Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Hands holding a multitude of pills © Credit Volodymyr Hryshchenko Unsplash

Collaborating scientists at Flinders University and University of Adelaide, Australia, conducted massively parallel sequencing to compare eDNA signatures between falsified and genuine antimalarials collected in Southeast Asia. They found a much greater diversity of eDNA in the falsified tablets, with differences between the diverse falsified packaging types, and also traces of human DNA.  

They coined the term ‘pharmabiome’ for the genetic signatures found in medicines and suggest that these techniques could be used to help trace the origins of falsified medicines.

This work is being expanded as part of the FORESFA Wellcome Collaborative Award to the Medicine Quality Research Group.

Read the publications 'Environmental DNA as an innovative technique to identify the origins of falsified antimalarial tablets—a pilot study of the pharmabiome' on the Nature website.

Similar stories

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Constant genetic surveillance necessary to keep multidrug-resistant malaria parasite strains in check, study finds

Continually monitoring malaria parasite populations is necessary to prevent outbreaks of previously dormant multidrug-resistant malaria strains, say University of Oxford researchers. Multidrug-resistant malaria parasite strains can rapidly grow or collapse in response to public health policy changes, say the researchers in a study published today in The Lancet.